We expect a 1:1 mutant‐to‐wildtype allele ratio in the TCGA ER+ breast cancer sample set to present as a 35:65 mutant‐to‐wildtype allele ratio for a few reasons: TCGA ER+ breast cancer samples have approximately 75% tumor purity,21 and copy number data from the TCGA demonstrate that no amplifications or deletions coincide with MLL3 mutations for these samples (Figure S1D). Here, KMT2C is linked to breast carcinoma.